Reported 2 days ago
Merck's first-quarter adjusted profit rose by 7% to $5.61 billion, despite a 2% sales decline due to lower demand for its Gardasil vaccine in China. The company anticipates a slight decrease in its annual earnings outlook, citing an extra $200 million in tariffs and other costs. While global sales fell to $15.5 billion, they remained above analyst expectations. Keytruda sales grew by 4%, though below projections, and Merck maintains its overall sales expectations for 2025.
Source: YAHOO